12879_2021_6257_MOESM1_ESM.pdf (353.53 kB)
Additional file 1 of Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
journal contribution
posted on 2021-06-17, 04:07 authored by Bianca A. Trombetta, Savannah E. Kandigian, Robert R. Kitchen, Korneel Grauwet, Pia Kivisäkk Webb, Glenn A. Miller, Charles G. Jennings, Sejal Jain, Samara Miller, Yikai Kuo, Thadryan Sweeney, Tal Gilboa, Maia Norman, Daimon P. Simmons, Christopher E. Ramirez, Melissa Bedard, Catherine Fink, Jina Ko, Esmarline J. De León Peralta, Gerald Watts, Emma Gomez-Rivas, Vannessa Davis, Rocky M. Barilla, Jianing Wang, Pierre Cunin, Samuel Bates, Chevaun Morrison-Smith, Benjamin Nicholson, Edmond Wong, Leena El-Mufti, Michael Kann, Anna Bolling, Brooke Fortin, Hayden Ventresca, Wen Zhou, Santiago Pardo, Megan Kwock, Aditi Hazra, Leo Cheng, Q. Rushdy Ahmad, James A. Toombs, Rebecca Larson, Haley Pleskow, Nell Meosky Luo, Christina Samaha, Unnati M. Pandya, Pushpamali De Silva, Sally Zhou, Zakary Ganhadeiro, Sara Yohannes, Rakeisha Gay, Jacqueline Slavik, Shibani S. Mukerji, Petr Jarolim, David R. Walt, Becky C. Carlyle, Lauren L. Ritterhouse, Sara SulimanAdditional file 1: Supplementary Methods. Supplementary Table 1. LFA commercial kit information, sample requirements, and protocol details. Supplementary Table 2. IFU clarity rubric. Supplementary Table 3. Usability ratings and description of kit components. Supplementary Table 4. Clinical information for the COVID-positive individuals whose plasma was used in this study. Supplementary Table 5. LFA Limits of detection estimated from anti-spike antibodies concentrations measured by Simoa.
